



CHUGAI PHARMABODY RESEARCH PTE. LTD.
INNOVATION BEGINS WITH ME





About CHUGAI PHARMABODY RESEARCH PTE. LTD. (CPR)

CPR was established in Singapore in January 2012 as a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd., a member of the Roche Group. Our mission is to discover innovative antibody and cyclic peptide drugs that significantly improve the lives of patients with unmet medical needs, thus contributing to the international medical community. CPR possesses various R&D facilities, ranging from lead identification and optimization to pharmacokinetics and pharmacology. With Singapore's innovative environment for world-class biomedical research, highly trained and multi-national scientists, and government support, we are a global leader in both antibody and cyclic peptide drug discovery.

Additional information is available at <https://www.chugai-pharmabody.com/>



Join us and be part of a Global Top Pharmaceutical Company

About OUR PEOPLE



154 Employees
10 Nationalities
Various Expertise
As of 1 October 2025



Work as a unified team
committed to making the best
use of our R&D investments,
resources and talents

Acknowledging our people's contribution, no matter how small it is
Recognizing their efforts, not just by management but by each other
Trust, placing trust in our people to empower them



2024 X'mas Party

Sir David Lane, Chairman of the Board of CPR

CPR is proud to have Sir David Lane as Chairman of the Board. Sir David believes CPR wields a world-leading platform for drug discovery, contributing to innovation and generating a product pipeline that helps patients around the world.

About CHUGAI PHARMACEUTICAL CO., LTD. (CHUGAI)

Chugai Pharmaceutical is a leading research-based pharmaceutical company based in Tokyo, Japan. As an important member of the Roche Group, Chugai is actively involved in global R&D activities and has provided innovative products for various diseases and unmet medical needs.


Additional information is available on the internet at <https://www.chugai-pharm.co.jp/english/>.



About OUR SCIENCE

CPR works on drug discovery with our proprietary, top-level antibody engineering and cyclic peptide technology for various diseases, including oncological, inflammatory, fibrotic, and genetic disease. Research into greater depths of disease biology enables development of new research concepts for innovative drug conception.

Expanding drug target universe by technology




While druggable targets are limited by conventional antibody technology, our proprietary antibody and cyclic peptide technologies enable the expansion of the drug target universe, distinguishing ourselves from others. We can harness our unique technologies to comprehend disease biology for conceiving unprecedented modes of action in drug targets while continuously and independently developing newer technologies that unlock new fields of drugs.

Our proprietary technologies expand the drug target universe

Recycling antibody technology

allows single antibody molecule to bind to an antigen multiple times while conventional antibody can only once¹⁾. Applied to FDA-approved product, satralizumab.




Bispecific antibody technology

develops antibodies to bind to two distinct antigens, enabling a unique mode of action that satisfies unmet medical need²⁾³⁾. Applied to FDA-approved product, emicizumab.




Switch antibody technology

designs antibodies that specifically bind to the target antigen in the tumor microenvironment without detectable binding to antigen in plasma and normal tissue⁴⁾.



Cyclic peptide technology allows targeting intracellular protein-protein interaction via oral administration⁵⁾.



Reference

- 1) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. *Nat Biotechnol.* 2010, 1203-7.
- 2) A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. *Nat Med.* 2012, 1570-4.
- 3) An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. *Sci Transl Med.* 2017, 9(410).
- 4) Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation. *Cancer Discovery*, 2020.
- 5) Images created using MOL* should cite the PDB ID, the corresponding structure publication, Mol* (doi:10.2312/molva.20181103) and RCSB PDB (PDB ID 1QNG).

CPR Global Research and Development network



CHUGAI PHARMABODY RESEARCH PTE. LTD.
Singapore



CHUGAI PHARMACEUTICAL CO., LTD
Japan



ROCHE
Switzerland



GENENTECH
USA



CHUGAI PHARMABODY RESEARCH PTE. LTD.

3 Biopolis Drive, #07-11 to 16, Synapse, Singapore 138623

TEL: +65 6933 4888 • FAX: +65 6684 2257